Verastem Oncology has shared a different spin on what its near-approval treatment for low-grade serous ovarian cancer (LGSOC) could mean for patients, publishing survey results that dig into the ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of ...

As of the cutoff date of March 31, 2025, GenFleet reported that no dose-limiting toxicities (DLTs) were observed across all dose levels (100-900 mg QD), and the treatment-related adverse events (TRAEs ...

We expect investors to focus on Verastem Oncology’s VSTM progress with the development of its pipeline candidates being studied for various cancer indications when it reports first-quarter 2025 ...

BTIG raised the firm’s price target on Verastem (VSTM) to $20 from $13 and keeps a Buy rating on the shares after the company announced the FDA accepted its new drug application filing for ...

Verastem (VSTM) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the ...

COPIKTRA is an important addition to the evolving treatment paradigm for patients with CLL/SLL and FL. The approval of COPIKTRA for the treatment of relapsed or refractory CLL/SLL after at least two ...

On an unaudited basis, Verastem expects preliminary Avmapki Fakzynja Co-pack net product revenues of approximately $17.5 ...

BOSTON--(BUSINESS WIRE)--Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the ...

The emergence of next-generation KRAS G12C inhibitors has led Verastem Oncology to change course. The Boston biotech has decided to discontinue a phase 1/2 trial in advanced KRAS G12C-mutated ...

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the grant of stock options to purchase 164,500 shares of ...